Literature DB >> 21036463

Vardenafil decreases bladder afferent nerve activity in unanesthetized, decerebrate, spinal cord-injured rats.

Delphine Behr-Roussel1, Stephanie Oger, Stéphanie Caisey, Peter Sandner, Jacques Bernabé, Laurent Alexandre, Francois Giuliano.   

Abstract

BACKGROUND: Phosphodiesterase type 5 inhibitors (PDE5-Is) improve storage symptoms in benign prostatic hyperplasia patients, despite a lack of effect on peak urinary flow rate. Moreover, vardenafil improves urodynamic parameters in spinal cord-injured (SCI) patients with neurogenic detrusor overactivity (NDO). SCI rats also display NDO characterized by nonvoiding contractions (NVCs) during bladder filling, resulting in an increased bladder afferent nerve firing (BANF).
OBJECTIVE: We postulated that vardenafil could improve urodynamic parameters by reducing BANF. The effect of vardenafil has been investigated on intravesical pressure by cystometry experiments while recording BANF in response to bladder filling. DESIGN, SETTING, AND PARTICIPANTS: Complete T7-T8 spinalization was performed in 15 female adult Sprague-Dawley rats (250-275 g). MEASUREMENTS: At 21-29 d postspinalization, fine filaments were dissected from the L6 dorsal roots and placed across a bipolar electrode. Bladder afferent nerve fibers were identified by electrical stimulation of the pelvic nerve and bladder distension. SCI rats were decerebrated before cystometry experiments. Bladders were filled to determine the maximal bladder filling volume (BFV) for each rat. Then, after bladder stabilization at 75% of maximal BFV, saline (n=7) or vardenafil 1 mg/kg (n=8) was delivered intravenously. NVCs and BANF were recorded for 45 min. RESULTS AND LIMITATIONS: In all SCI rats, BANF was already present and regular at resting conditions (26.2±4.1 spikes per second). During bladder filling, intravesical pressure (IVP) slowly increased with transient NVCs superimposed. Concomitantly, BANF progressively increased up to 2.4-fold at maximal BFV (2.08±0.24 ml). After stabilization at submaximal BFV, BANF was increased by 186±37%. Vardenafil injection induced an immediate decrease in NVCs compared to saline (p<0.001) and BANF (52% decrease vs 28% in saline after 45 min; p<0.001).
CONCLUSIONS: Systemic vardenafil reduced both NVCs and BANF in unanesthetized, decerebrate, SCI rats. These findings provide new insights into the mechanism of action by which PDE5-Is improve storage symptoms in SCI patients. Copyright Â
© 2010 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21036463     DOI: 10.1016/j.eururo.2010.10.037

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  20 in total

1.  Are phosphodiesterase type 5 inhibitors effective for the management of lower urinary symptoms suggestive of benign prostatic hyperplasia?

Authors:  Li Tao Zhang; Jong Kwan Park
Journal:  World J Nephrol       Date:  2015-02-06

Review 2.  The link between vascular dysfunction, bladder ischemia, and aging bladder dysfunction.

Authors:  Karl-Erik Andersson; Donna B Boedtkjer; Axel Forman
Journal:  Ther Adv Urol       Date:  2016-11-04

3.  The correlation between lower urinary tract symptoms (LUTS) and erectile dysfunction (ED): results from a survey in males from Mexico City (MexiLUTS).

Authors:  Benjamin Gonzalez-Sanchez; Jesus Cendejas-Gomez; J Alejandro Rivera-Ramirez; Jaime O Herrera-Caceres; Daniel Olvera-Posada; Christian I Villeda-Sandoval; Ricardo A Castillejos-Molina; Guillermo Feria-Bernal; Arturo Garcia-Mora; Francisco Rodriguez-Covarrubias
Journal:  World J Urol       Date:  2015-10-14       Impact factor: 4.226

Review 4.  Tadalafil for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a review of clinical data in Asian men and an update on the mechanism of action.

Authors:  Osamu Yokoyama; Yasuhiko Igawa; Masayuki Takeda; Takafumi Yamaguchi; Masahiro Murakami; Lars Viktrup
Journal:  Ther Adv Urol       Date:  2015-10

Review 5.  Non-surgical urologic management of neurogenic bladder after spinal cord injury.

Authors:  Paholo G Barboglio Romo; Christopher P Smith; Ashley Cox; Márcio A Averbeck; Caroline Dowling; Cleveland Beckford; Paul Manohar; Sergio Duran; Anne P Cameron
Journal:  World J Urol       Date:  2018-07-26       Impact factor: 4.226

Review 6.  Research Findings on Overactive Bladder.

Authors:  Phani B Patra; Sayani Patra
Journal:  Curr Urol       Date:  2015-05-20

Review 7.  The role of phosphodiesterases in bladder pathophysiology.

Authors:  Mohammad S Rahnama'i; Stefan Ückert; Ramona Hohnen; Gommert A van Koeveringe
Journal:  Nat Rev Urol       Date:  2013-05-14       Impact factor: 14.432

Review 8.  The role of phosphodiesterase type-5 inhibitors in treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia.

Authors:  Mehmet Umul; Tekin Ahmet Serel
Journal:  Turk J Urol       Date:  2013-12

Review 9.  Phosphodiesterase-5 expression and function in the lower urinary tract: a critical review.

Authors:  Ching-Shwun Lin; Maarten Albersen; Zhongcheng Xin; Mikio Namiki; Dieter Muller; Tom F Lue
Journal:  Urology       Date:  2013-01-17       Impact factor: 2.649

Review 10.  A review of the use of tadalafil in the treatment of benign prostatic hyperplasia in men with and without erectile dysfunction.

Authors:  Konstantinos Hatzimouratidis
Journal:  Ther Adv Urol       Date:  2014-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.